Concomitant high apoptosis inhibitor of macrophage (Aim) and low prostate-specific antigen (psa) indicates activated t cell-mediated anticancer immunity, enhance sensitivity to pembrolizumab, and elicit good prognosis in prostate cancer

研究成果: 雜誌貢獻文章同行評審

指紋

深入研究「Concomitant high apoptosis inhibitor of macrophage (Aim) and low prostate-specific antigen (psa) indicates activated t cell-mediated anticancer immunity, enhance sensitivity to pembrolizumab, and elicit good prognosis in prostate cancer」主題。共同形成了獨特的指紋。

Medicine & Life Sciences

Chemical Compounds